A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus

Cancer Journal

Volumn 6, Issue 5, 2000, Pages 316-323

  Ilson, D H ^a   Forastiere, A ^a   Arquette, M ^a   Costa, F ^a   Heelan, R ^a   Huang, Y ^a   Kelsen, D P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cisplatin; Dysphagia; Esophageal adenocarcinoma; Metastatic disease; Paclitaxel

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DYSPHAGIA; ESOPHAGUS CARCINOMA; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; TIME FACTORS;

EID: 0033764273     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Cancer statistics, 1999
2. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
3. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia
4. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia
5. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: Results and commentary
6. Randomized phase II study of cisplatin and 5-FU versus cisplatin alone in advanced squamous cell oesophageal cancer
7. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
8. Promotion of microtubule assembly in vitro by Taxol
9. The taxanes: Dosing and scheduling considerations
10. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus
11. Phase I and pharmacokinetic trial of a 3 hour infusion of Taxol, cisplatin plus 5-fluorouracil in advanced solid tumors
12. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with adanced carcinoma of the esophagus
13. Sequences of Taxol and cisplatin: A phase I and pharmacologic study
14. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
15. The Fox Chase Cancer and Free University Hospital Investigator's Workshop and Consensus Conference on Paclitaxel Part 2: Gynecologic and Genitourinary Malignancies
16. The Fox Chase Cancer and Free University Hospital investigator's Workshop and Consensus Conference on Paclitaxel Part 2: Gynecologic and Genitourinary Malignancies
17. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: Rapid development of neurotoxicity is dose-limiting
18. Reporting of cancer treatment
19. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer
20. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent
21. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma
22. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting
23. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity
24. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: Results of a multicenter phase II trial
25. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: A phase II study of the Fox Chase Cancer Center and its network
26. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: Preliminary results comparing sequential phase II trials
27. Chemotherapy withcisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer
28. Biweekly administration of cisplatin and increasing doses of paclitaxel in patients with advanced esophageal cancer [abstract]
29. Chemotherapy in esophageal cancer
30. Phase II study of paclitaxel and carboplatin in patients with advanced gastric and esophageal cancers
31. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer
32. A regimen of paclitaxel (P), cisplatin (CP) and 5-fluorouracil (FU) followed by G-CSF is highly active against epidermoid and adenocarcinoma of esophagus [abstract]
33. Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus
34. Gastrointestinal Cancer Poster Session
35. A phase I/II trial of preoperative Taxol, cisplatin, 5-FU and concurrent boost radiation in esophageal cancer
36. Preoperative thearpy with paclitaxel, carboplatin, 5-FU and radiation in the treatment of local esophageal cancer
37. Neoadjuvant paclitaxel, cisplatin and radiation for esophageal cancer
38. Phase I trial of combined modality therapy for localized esophageal cancer: Radiation therapy + concurrent cisplatin and escalating doses of 96 hour infusional paclitaxel [abstract]